loading
Amphastar Pharmaceuticals Inc stock is currently priced at $41.24, with a 24-hour trading volume of 185.59K. It has seen a +1.05% increased in the last 24 hours and a -4.52% declined in the past month. The chart indicates a potential bullish trend, as the stock is above the $40.76 pivot point. If it approaches the $41.44 resistance level, significant changes may occur.
Previous Close:
$40.83
Open:
$40.77
24h Volume:
185.59K
Market Cap:
$2.01B
Revenue:
$644.40M
Net Income/Loss:
$137.55M
P/E Ratio:
21.15
EPS:
1.95
Net Cash Flow:
$145.34M
1W Performance:
+3.12%
1M Performance:
-4.52%
6M Performance:
-8.19%
1Y Performance:
+8.12%
1D Range:
Value
$40.50
$41.42
52W Range:
Value
$35.62
$67.66

Amphastar Pharmaceuticals Inc Stock (AMPH) Company Profile

Name
Name
Amphastar Pharmaceuticals Inc
Name
Phone
909-980-9484
Name
Address
11570 6th Street, Rancho Cucamonga, CA
Name
Employee
1,644
Name
Twitter
Name
Next Earnings Date
2024-05-07
Name
Latest SEC Filings
Name
AMPH's Discussions on Twitter

Amphastar Pharmaceuticals Inc Stock (AMPH) Upgrades & Downgrades

Date Action Analyst Rating Change
Nov-17-23 Initiated BofA Securities Neutral
Jul-25-23 Resumed Jefferies Buy
Oct-21-22 Resumed Jefferies Buy
Jul-29-22 Initiated CapitalOne Overweight
Jan-07-22 Upgrade Piper Sandler Neutral → Overweight
Jan-08-21 Downgrade Wells Fargo Overweight → Equal Weight
Oct-05-20 Upgrade Northland Capital Market Perform → Outperform
May-01-20 Initiated Northland Capital Outperform
Mar-13-19 Downgrade Needham Buy → Hold
Mar-13-19 Downgrade Piper Jaffray Overweight → Neutral
Aug-10-18 Reiterated Needham Buy
Mar-13-18 Reiterated Needham Buy
Dec-01-17 Reiterated Needham Buy
Nov-09-17 Downgrade Raymond James Outperform → Mkt Perform
Sep-27-17 Reiterated Needham Buy
Mar-14-17 Downgrade Raymond James Strong Buy → Outperform
Aug-09-16 Reiterated Needham Buy
May-10-16 Reiterated Needham Buy
Feb-19-16 Initiated Wells Fargo Outperform
Jun-19-15 Reiterated Needham Buy
Jun-03-15 Initiated Raymond James Strong Buy
Jul-21-14 Initiated Needham Buy
View All

Amphastar Pharmaceuticals Inc Stock (AMPH) Financials Data

Amphastar Pharmaceuticals Inc (AMPH) Revenue 2024

AMPH reported a revenue (TTM) of $644.39 million for the quarter ending December 31, 2023, a +29.14% rise year-over-year.
loading

Amphastar Pharmaceuticals Inc (AMPH) Net Income 2024

AMPH net income (TTM) was $137.54 million for the quarter ending December 31, 2023, a +50.51% increase year-over-year.
loading

Amphastar Pharmaceuticals Inc (AMPH) Cash Flow 2024

AMPH recorded a free cash flow (TTM) of $145.34 million for the quarter ending December 31, 2023, a +123.09% increase year-over-year.
loading

Amphastar Pharmaceuticals Inc (AMPH) Earnings per Share 2024

AMPH earnings per share (TTM) was $2.58 for the quarter ending December 31, 2023, a +46.59% growth year-over-year.
loading

Amphastar Pharmaceuticals Inc Stock (AMPH) Insider Trading

Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total
Zhang Jack Y.
CEO & Chief Scientific Officer
Mar 15 '24
Option Exercise
12.46
722,046
8,996,693
2,858,043
Zhang Jack Y.
CEO & Chief Scientific Officer
Mar 15 '24
Option Exercise
12.46
310,930
3,874,188
1,439,466
PETERS WILLIAM J
CFO, EVP & TREASURER
Mar 06 '24
Option Exercise
11.33
8,826
99,999
129,626
PETERS WILLIAM J
CFO, EVP & TREASURER
Mar 06 '24
Sale
46.48
18,136
842,883
111,490
ZASLOFF MICHAEL A
Director
Mar 05 '24
Sale
47.18
12,500
589,724
21,326
Petersen Floyd F.
Director
Mar 01 '24
Sale
45.69
500
22,847
79,833
Petersen Floyd F.
Director
Feb 01 '24
Sale
53.10
500
26,548
80,333
Luo Mary Z.
COO,Chief Scientist & Chairman
Jan 10 '24
Sale
54.59
131,386
7,171,768
1,104,416
Luo Mary Z.
COO,Chief Scientist & Chairman
Jan 09 '24
Sale
57.14
86,156
4,923,232
1,235,802
Luo Mary Z.
COO,Chief Scientist & Chairman
Jan 08 '24
Sale
58.93
133,644
7,875,476
1,321,958
Amphastar Pharmaceuticals, Inc., a specialty pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States and internationally. It operates through two segments, Finished Pharmaceutical Products and Active Pharmaceutical Ingredients. The company offers enoxaparin, a low molecular weight heparin that is used as an anticoagulant for the prevention and treatment of deep vein thrombosis; naloxone for opioid overdose; Cortrosyn, a lyophilized powder for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency; Amphadase, a bovine-sourced hyaluronidase injection to absorb and disperse other injected drugs; and lidocaine jelly, a local anesthetic product for urological procedures. It also provides lidocaine topical solution for various procedures; phytonadione injection for newborn babies; syringe products, such as morphine, atropine, calcium chloride, dextrose, epinephrine, lidocaine, and sodium bicarbonate for emergency use in hospital settings; lorazepam injection for surgery and medical procedures; ketorolac for acute pain management; procainamide for documented ventricular arrhythmias; medroxyprogesterone acetate injectable suspension for the prevention of pregnancy. In addition, the company manufactures and distributes recombinant human and porcine insulins. Further, it develops Primatene Mist, an over-the-counter epinephrine inhalation product candidate for the temporary relief of mild symptoms of intermittent asthma. Additionally, the company has a pipeline of 20 generic and proprietary product candidates in various stages of development for various indications. Its products are used in hospital or urgent care clinical settings, and primarily contracted and distributed through group purchasing organizations and drug wholesalers. Amphastar Pharmaceuticals, Inc. was founded in 1996 and is headquartered in Rancho Cucamonga, California.
$13.32
price up icon 2.15%
$72.78
price up icon 0.96%
$56.01
price up icon 0.39%
drug_manufacturers_specialty_generic RDY
$74.61
price up icon 0.80%
$11.64
price up icon 1.44%
$136.35
price down icon 0.97%
Cap:     |  Volume (24h):